←
David Erlinge93 posts
David Erlinge avatar

David Erlinge

@DavidErlinge
◷ Joined August 2016▧ 5 Photos and videos
Mamas A. Mamas avatar
⟳ David Erlinge retweeted
Mamas A. Mamas@mmamas1973·8 Nov 2024

Congratulations to @YndigegnY for a successful defence of his PhD today (1st author of REDUCE-AMI trial doi.org/10.1056/nejmoa240147… ) at the University of Lund (I was the external examiner) with supervisors @AlexSchiopu10 and @DavidErlinge This was a public examination with a strong defence. Thankfully Mrs Yndigegn is still inviting me to the evening dinner celebration in honour of her husband 😜 Thank you to David and Alex for hosting me in Lund with a memorable dinner last night

Post attachmentPost attachmentPost attachment
Gregg W. Stone MD avatar
⟳ David Erlinge retweeted
Gregg W. Stone MD@GreggWStone·6 Oct 2024

Our latest PROSPECT II pub in Circ CV Int supports a possible use for NIRS during PCI. FU stent edge–related MACE was ↑ if post-PCI stent edge maxLCBI4mm was >~100 with stent edge plaque burden >50% (adj OR 4.11). Suggests slightly longer stents to cover lipid MAY ↓MACE.

Post attachmentPost attachment
Cardiovascular Research Foundation avatar
⟳ David Erlinge retweeted
Cardiovascular Research Foundation@crfheart·21 Oct 2024

🔬 Get ready for the latest in cardiovascular research! Dr. @DavidErlinge will reveal findings from the INFINITY-SWEDEHEART trial on Monday, October 28. Be part of the first to see major clinical trials and transformative science at #TCT2024! Claim your spot today: tct2024.crfconferences.com/r… 📅 Explore the full schedule of late-breaking trials and innovative studies here: tct2024.crfconferences.com/l… #CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMd @djc795 @georgedangas @jgranadacrf @MartyBLeon @MaeharaAkiko @Drroxmehran @sahilparikhmd @triciarawh @TCTConference @jedicath @Dr_ibrahimHarbi @Almanfi_Cardio @BakhshiHooman @ABeneduceMD @nyalborgesmd @aayshacader @BCase07 @NishithChandra @baileyannRN @fischman_david @hect2701 @JGrapsa @HamidNadira @stefan_harb @AmandaLimaMD @evandrofilhobr @GiorgioMedranda @mornei2011 @SrihariNaiduMD @sumonroy_md @DocSavageTJU @Shoaib9702 @poojaotherwise @iamritu @atunuguntla1 @Pooh_Velagapudi @EZancanaroMD @AdrianaCMares @NielsRHolm @IAmDoctorAbhi @KrutarthKPandya @IndahSP_MD @ShariqShamimMD @mirvatalasnag

1:36
Davide Capodanno avatar
⟳ David Erlinge retweeted
Davide Capodanno@DFCapodanno·16 Apr 2024

I am passionate about neutral studies, but only when their results are true negatives, not false negatives due to low statistical power. I particularly appreciate them when they eliminate drugs with seemingly routine indications but are actually poorly supported by literature or developed in an era where it was easy to beat placebo. Think of beta-blockers in REDUCE-MI. Or what is happening in the aspirin-free realm. These "x-free studies" could be a new research trend, where randomized registries have tremendous potential. Imagine a statin-free study in patients with PCSK9 inhibitors. Where is it written that we must always test drugs in addition? Couldn't we test drugs in subtraction more often?

Post attachment
Troels Yndigegn MD PhD avatar
⟳ David Erlinge retweeted
Troels Yndigegn MD PhD@YndigegnY·8 Apr 2024

The REDUCE-AMI trial is the only trial powered to guide decision in post MI-patients with LV =/>50%. The KM-curves are virtually overlapping and if cross-over was supposed to affect the result one would expect an early delta which would disappear and this is not the case.

Post attachment
C. Michael Gibson MD avatar
⟳ David Erlinge retweeted
C. Michael Gibson MD@CMichaelGibson·27 Oct 2023

Use of AI to integrate plaque composition characteristics that increase risk for ACS 1. delta FFR across lesion 2. Plaque location & burden at site 3. Total plaque volume 4. Low attenuation plaque volume 5. Percent myocardial blood flow Lumen narrowing not as important !! #snackablehealth s/b HeartFlow

7:34
Sam Tsimikas, MD avatar
⟳ David Erlinge retweeted
Sam Tsimikas, MD@Lpa_Doc·5 Jul 2023

An area of Lp(a) research that is lacking is outcomes post PCI/CABG. Data suggests pts with ⏫ Lp(a) have worse outcomes. @hsbhatia @DavidErlinge and I outline 2 trials, one pragmatic, to assess if outcomes can be improved. TY to @LipidJournal for opportunity to share thoughts

Post attachment
Gregg W. Stone MD avatar
⟳ David Erlinge retweeted
Gregg W. Stone MD@GreggWStone·27 Mar 2023

First 3-vessel OCT imaging study publ in JACC w/long-term FU showing OCT can identify vulnerable plaques with strong discrimination. Our editorial on whether inv imaging (OCT, NIRS-IVUS, RF-IVUS) can detect VP: "Case Closed"! There are now at least 10 good studies! @ziadalinyc

Post attachmentPost attachmentPost attachmentPost attachment
Niels R. Holm avatar
⟳ David Erlinge retweeted
Niels R. Holm@NielsRHolm·5 Mar 2023

One more RCT showing better prognosis after imaging-guided PCI vs standard angio-guided PCI. What are we waiting for? #updateguidelines #cardiotwitter

NEJM@NEJM5 Mar 2023

In RENOVATE-COMPLEX-PCI, a randomized trial of imaging-guided or angiography-guided PCI for complex coronary lesion revascularization procedures, imaging-guided PCI led to a lower risk of target-vessel failure than angiography-guided PCI. nej.md/3Y2zION #ACC23/#WCCardio

Post attachment